Official UK procurement notice
Ustekinumab and Omalizumab · UK public procurement notice
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) (NHS & healthcare)·Consortium: 2 public authorities
What is being bought2 lots · detail below
Published requirement descriptionSupply of Ustekinumab and Omalizumab to NHS Scotland
CPV: Pharmaceutical products
How this framework works
From the published notice- Places
- up to 6 suppliers · 6 bids on the busiest of 2 lots (1.0 per place) · 7 appointed (full)
Lots and requirements (2)Procurement structure
2 lots · no lot values published · evaluation weights differ by lotLot #1UstekinumabAwardedRenewal
Supply of Ustekinumab presentations to NHS Scotland. The Authority has awarded this Lot as an unranked multi-supplier framework per product line to a six (6) Framework Participants.
Lot #2OmalizumabAwardedRenewal
Supply of Omalizumab presentations to NHS Scotland. The Authority has awarded this Lot as an unranked multi-supplier framework per product line to two (2) Framework Participants.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Lots publish different evaluation splits; there is no single procedure weighting.
| Lot | Quality | Price | Split |
|---|---|---|---|
| 1 · Ustekinumab | 5% | 95% | |
| 2 · Omalizumab | 5% | 95% |
- Suitability
Economic operators may be excluded from this competition if they are in breach of any
situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.
- Technical & professional ability
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB, or PLPI number) that has been approved by the MHRA for all tendered Medicines at the start date of the Framework Agreement.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid
certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.
Minimum: (a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB, PLPI number) that has been approved by the MHRA for all tendered Medicines at the start date of the Framework Agreement should be included in the Qualification Envelope of the ITT under the…
- Price carries 95 points on every lot: a 10% discount moves about 9.5 points.
- “Ustekinumab and Omalizumab” is a framework: the contest is a place on its panel, up to 6 suppliers, not a single contract.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 28 Jun 2024, 10:28 BST
- Last source update
- 11 Sept 2024, 16:09 BST
- Award evaluation window
- 29 Jul 2024 – …
- Authority reference
NP47924de- FTS notice number
2024/S 000-029144- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-047344Find a Tender
- Electronic trading
- electronic ordering
- Review procedure
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.
The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.
Publisher note: (SC Ref:777753)
How it was run
Official notice- Appointment period ends
- 29 Jul 2024, 12:00 BST
- Submission channel
- {"electronicSubmission"}
- Accepted languages
- en
- Bids opened
- 29 Jul 2024, 13:30 BST
Timeline
29 Jul 2024 → 30 Oct 2024 · 4 dates- Admission / appointment period endsperiod end, not a bid countdown29 Jul 2024, 12:00 BST
- Bids opened29 Jul 2024, 13:30 BST
- Notice published11 Sept 2024, 16:09 BST
- Bids must remain valid until30 Oct 2024, 23:59 GMT
Notice history
2 events · 2 releases on Find a Tender · since 11 Sept 2024- Status changed to complete11 Sept 2024, 16:09 BST
- Buyer details updated11 Sept 2024, 16:09 BST
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast2 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
Ustekinumab
- Signed
- 21 Aug 2024
- Value
- £11,680,128
- Status
- active
Omalizumab
- Signed
- 21 Aug 2024
- Value
- £2,136,450
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · Ustekinumab | 6bids · 6 electronic · 6 from abroad | 4 | — | — |
| 2 · Omalizumab | 2bids · 2 electronic · 2 from abroad | 2 | — | — |
Contracting authority & participating public bodies
2 public bodies on the noticeDispute resolution & review bodies
- Sherriff Court HouseReview body
Framework contractors & participating bidders
7 commercial parties on the notice- Accord Healthcare LtdFramework contractor
- Amgen LtdFramework contractor
- Celltrion Healthcare United Kingdom LimitedFramework contractor
- Janssen-Cilag LtdFramework contractor
- Novartis Pharmaceuticals UK LtdFramework contractor
- STADA UK - Thornton & RossFramework contractor
- SandozFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.